Daniel J. Abrams, M.D., CEO
Dr. Abrams is the Chief Executive Officer and a Member of the Board of Directors of Cerebral Therapeutics. Prior to founding Cerebral Therapeutics, Dr. Abrams founded Sierra Neuropharmaceuticals, Inc.; raising $21.5 million in Series A venture capital. Dr. Abrams has practiced as a neurosurgeon and a psychiatrist and served as head of the Department of Neurosurgery at St. Joseph’s Hospital in Denver. Dr. Abrams’ expertise with implantable CNS infusion pumps, experience in cerebrospinal fluid drug delivery and in the use and development of CNS pharmaceutics makes him well suited to lead Cerebral Therapeutics development of implantable infusion systemic medications for patients with severe medically refractory epilepsy.
Lisa Shafer Ph.D., Chief Science Officer
Dr Lisa Shafer is the Chief Scientific Officer of Cerebral Therapeutics. Dr. Shafer’s technical and leadership experience in R&D, strategy, and business development spans medical device, biotechnology and pharmaceutical industries. Prior to joining Cerebral Therapeutics, Dr. Shafer served in R&D leadership positions at start-up, mid-size and large global pharmaceutical companies. Prior to joining the pharmaceutical side, Dr. Shafer spent over 10 years in the medical device industry. While at Medtronic Dr. Shafer held various roles in new ventures, drug-device combination product development, neuromodulation research, and management. Dr Shafer’s foundational research and leadership resulted in seminal publications regarding mechanistic, proof of concept and clinical evidence for a portfolio of translational and clinical research programs to advance brain targeted drug delivery. Dr. Shafer began her career at 3M in the Pharmaceutical and Drug Delivery Division and holds a B.S in Genetics and Cell Biology and a PhD in Neuroimmunology.
Eric Distad, Vice President of Clinical Development
Mr. Distad comes to Cerebral Therapeutics as Vice President of Clinical Development with over 24 years’ experience in medical device and combination product clinical development. Mr. Distad has been responsible for the development and management of over forty (40) IDE studies from protocol development through final submission to regulatory authorities. He has focused on Class III devices and drug-device combination products in the therapeutic areas of movement disorders and epilepsy. Prior to joining Cerebral Therapeutics, Mr. Distad’s experience included Global Program Management at Medtronic in the Cardiac Rhythm Management and Neuromodulation Divisions, start-up and early commercial orthopedic companies, as well as leadership roles at two large Clinical Research Organizations within their Global Medical Device and Combination Product Divisions. In addition, Mr. Distad has served as in advisory positions for Medical Technology Angel Funding groups, International Medical Device and Combination Product Regulatory Panels and Therapeutic Advisory Panels.